820 related articles for article (PubMed ID: 21990393)
21. Salvage treatment improved survival of patients with relapsed extranodal natural killer/t-cell lymphoma, nasal type.
Zhang XX; Xie CH; Xu Y; Deng D; Zhao YH; Zou BW; Zhou L; Li M; Wang J; Liu WP; Huang MJ
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):747-52. PubMed ID: 19304409
[TBL] [Abstract][Full Text] [Related]
22. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group.
Kwong YL; Kim WS; Lim ST; Kim SJ; Tang T; Tse E; Leung AY; Chim CS
Blood; 2012 Oct; 120(15):2973-80. PubMed ID: 22919026
[TBL] [Abstract][Full Text] [Related]
23. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH
Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682
[TBL] [Abstract][Full Text] [Related]
24. Early radiotherapy has an essential role for improving survival in patients with stage I-II nasal-type of NK/T cell lymphoma treated with L-asparaginase-containing chemotherapy--a single institution experience.
Zang J; Li C; Luo SQ; Wang JH; Xu M; Zhao LN; Li WW; Yang H; Xiao F; Hitchcock YJ; Shi M
Ann Hematol; 2015 Apr; 94(4):583-91. PubMed ID: 25409913
[TBL] [Abstract][Full Text] [Related]
25. A randomized phase II study of CEOP with or without semustine as induction chemotherapy in patients with stage IE/IIE extranodal NK/T-cell lymphoma, nasal type in the upper aerodigestive tract.
Ma X; Guo Y; Pang Z; Wang B; Lu H; Gu YJ; Guo X
Radiother Oncol; 2009 Dec; 93(3):492-7. PubMed ID: 19782419
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients.
Zhou Z; Li X; Chen C; Li X; Zhang L; Li L; Wang X; Ma W; Fu X; Wu J; Sun Z; Zhang X; Li Z; Yan J; Chang Y; Lu L; Qin B; Li X; Wen J; Zhang M
Ann Hematol; 2014 Nov; 93(11):1889-94. PubMed ID: 24923454
[TBL] [Abstract][Full Text] [Related]
27. High-dose methotrexate, etoposide, dexamethasone and pegaspargase (MEDA) combination chemotherapy is effective for advanced and relapsed/refractory extranodal natural killer/T cell lymphoma: a retrospective study.
Ding H; Chang J; Liu LG; Hu D; Zhang WH; Yan Y; Ma LY; Li ZC; Ma YJ; Hao SG; Tao R
Int J Hematol; 2015 Aug; 102(2):181-7. PubMed ID: 25997870
[TBL] [Abstract][Full Text] [Related]
28. Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.
Oh D; Ahn YC; Kim SJ; Kim WS; Ko YH
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):677-83. PubMed ID: 26461010
[TBL] [Abstract][Full Text] [Related]
29. A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type.
Xu PP; Xiong J; Cheng S; Zhao X; Wang CF; Cai G; Zhong HJ; Huang HY; Chen JY; Zhao WL
EBioMedicine; 2017 Nov; 25():41-49. PubMed ID: 29056540
[TBL] [Abstract][Full Text] [Related]
30. Trial of LVDP regimen (L-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III/IV extranodal natural killer/T cell lymphoma.
Wang YQ; Yang Y; Zhuo HY; Zou LQ; Jiang Y; Jiang M
Med Oncol; 2015 Feb; 32(2):435. PubMed ID: 25572807
[TBL] [Abstract][Full Text] [Related]
31. A phase II prospective study of the "Sandwich" protocol, L-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma.
Jiang M; Zhang L; Xie L; Zhang H; Jiang Y; Liu WP; Zhang WY; Tian R; Deng YT; Zhao S; Zou LQ
Oncotarget; 2017 Jul; 8(30):50155-50163. PubMed ID: 28404973
[TBL] [Abstract][Full Text] [Related]
32. Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008).
Yoon DH; Kim SJ; Jeong SH; Shin DY; Bae SH; Hong J; Park SK; Yhim HY; Yang DH; Lee H; Kang HJ; Lee MH; Eom HS; Kwak JY; Lee JH; Suh C; Kim WS
Oncotarget; 2016 Dec; 7(51):85584-85591. PubMed ID: 27542213
[TBL] [Abstract][Full Text] [Related]
33. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
[TBL] [Abstract][Full Text] [Related]
34. Comparative Study of L-Asparaginase-Based LOP Regimen Over CHOP Regimen Before Radiotherapy for Stage IIE Extranodal Nasal Type NK/T Cell Lymphoma: A Study of 2 Centers.
Huang L; Yuan B; Wu H; Chu H; Liu Y; Wu S; Li H; Lu H; Chen H
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):152-158. PubMed ID: 28215935
[TBL] [Abstract][Full Text] [Related]
35. Retrospective analysis of treatment outcomes for extranodal NK/T-cell lymphoma (ENKL), nasal type, stage I-IIE: single institute experience of combined modality treatment for early localized nasal extranodal NK/T-cell lymphoma (ENKL).
Lee J; Cho SG; Chung SM; Ryu MR; Kim SH; Jang HS; Choi BO
Ann Hematol; 2013 Mar; 92(3):333-43. PubMed ID: 23180438
[TBL] [Abstract][Full Text] [Related]
36. [Treatment option and outcome for patients with primary non-Hodgkin's lymphoma of the nasal cavity].
Yao B; Li YX; Song YW; Jin J; Liu YP; Wang WH; Wang SL; Sun YT; Yu ZH; Liu XF
Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):58-61. PubMed ID: 16737624
[TBL] [Abstract][Full Text] [Related]
37. A clinical study of 115 patients with extranodal natural killer/T-cell lymphoma, nasal type.
Wu X; Li P; Zhao J; Yang X; Wang F; Yang YQ; Fang F; Xu Y; Zhang H; Wang WY; Yi C
Clin Oncol (R Coll Radiol); 2008 Oct; 20(8):619-25. PubMed ID: 18790372
[TBL] [Abstract][Full Text] [Related]
38. NF-kappaB activation through the alternative pathway correlates with chemoresistance and poor survival in extranodal NK/T-cell lymphoma, nasal type.
Liu X; Wang B; Ma X; Guo Y
Jpn J Clin Oncol; 2009 Jul; 39(7):418-24. PubMed ID: 19395464
[TBL] [Abstract][Full Text] [Related]
39. Concurrent Etoposide, Steroid, High-dose Ara-C and Platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type.
Michot JM; Mazeron R; Danu A; Lazarovici J; Ghez D; Antosikova A; Willekens C; Chamseddine AN; Minard V; Dartigues P; Bosq J; Carde P; Koscielny S; De Botton S; Ferme C; Girinsky T; Ribrag V
Eur J Cancer; 2015 Nov; 51(16):2386-95. PubMed ID: 26254810
[TBL] [Abstract][Full Text] [Related]
40. A study of gemcitabine, l-asparaginase, ifosfamide, dexamethasone and etoposide chemotherapy for newly diagnosed stage IV, relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type.
Ji J; Liu T; Xiang B; Liu W; He C; Chen X; Li J; Chang H; Dai Y; Dong T
Leuk Lymphoma; 2014 Dec; 55(12):2955-7. PubMed ID: 24679007
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]